{
  "topic": {
    "stem": "NEMOLIZUMAB_PRURIGO_REVIEW",
    "name": "Nemolizumab in prurigo nodularis (OLYMPIA)",
    "ncts": [
      "NCT04501666",
      "NCT04204616"
    ],
    "drug_patterns": [
      "nemolizumab"
    ],
    "condition_patterns": [
      "prurigo"
    ]
  },
  "trials": [
    {
      "gates": {
        "A_aact_exists": true,
        "B_drug_in_intvs": true,
        "C_condition_in_aact": true,
        "D_pmid_topic_match": true,
        "E_two_arms": true,
        "F_primary_outcome_known": true
      },
      "extracted": {
        "nct": "NCT04501666",
        "aact_title": "Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)",
        "aact_acronym": "",
        "start_date": "2020-09-11",
        "primary_completion_date": "2022-11-11",
        "aact_intvs": [
          "Nemolizumab 30 mg",
          "Placebo"
        ],
        "aact_conditions": [
          "prurigo nodularis"
        ],
        "pmid": "37888917",
        "pubmed_year": 2023,
        "pubmed_doi": "10.1056/NEJMoa2301333",
        "aact_per_arm_counts": {
          "BG000": 190,
          "BG001": 96
        },
        "aact_primary_outcome_measure": "Number of Participants With an Improvement of Greater Than or Equal to (>=) 4 From Baseline in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16",
        "aact_outcome_count_rows": [
          [
            "OG000",
            "111.0"
          ],
          [
            "OG001",
            "16.0"
          ],
          [
            "OG000",
            "50.0"
          ],
          [
            "OG001",
            "7.0"
          ],
          [
            "OG000",
            "134.0"
          ],
          [
            "OG001",
            "62.0"
          ],
          [
            "OG000",
            "32.0"
          ],
          [
            "OG000",
            "16.0"
          ],
          [
            "OG001",
            "18.0"
          ],
          [
            "OG001",
            "10.0"
          ]
        ]
      }
    },
    {
      "gates": {
        "A_aact_exists": true,
        "B_drug_in_intvs": true,
        "C_condition_in_aact": true,
        "D_pmid_topic_match": true,
        "E_two_arms": false,
        "F_primary_outcome_known": true
      },
      "extracted": {
        "nct": "NCT04204616",
        "aact_title": "A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)",
        "aact_acronym": "",
        "start_date": "2021-01-11",
        "primary_completion_date": "2026-10-26",
        "aact_intvs": [
          "Nemolizumab"
        ],
        "aact_conditions": [
          "prurigo nodularis"
        ],
        "pmid": "41405008",
        "pubmed_year": 2025,
        "pubmed_doi": "10.1111/jdv.70266",
        "aact_per_arm_counts": {},
        "aact_primary_outcome_measure": "Incidence of Adverse Events (AEs) by Severity",
        "aact_outcome_count_rows": []
      }
    }
  ],
  "gate_summary": {
    "A_aact_exists": 2,
    "B_drug_in_intvs": 2,
    "C_condition_in_aact": 2,
    "D_pmid_topic_match": 2,
    "E_two_arms": 1,
    "F_primary_outcome_known": 2
  },
  "n_total": 2,
  "n_pass_all": 1,
  "pass_rate": 0.5,
  "verdict": "VIABLE"
}